News Column

Nodality, Inc. Expands Intellectual Property Estate, Announces U.S. Patent for Broadly Enabling Single Cell Network Profiling (SCNP) Technology Platform

August 14, 2014



SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Nodality, Inc., an innovative biotechnology company advancing discovery, development and use of transformative therapies across broad therapeutic categories, with a focus on immunology and oncology, including immuno-oncology, announced today the expansion of its patent portfolio with the issuance of U.S. Patent No. 8,815,527, “Methods and Compositions for Detecting the Activation State of Multiple Proteins in Single Cells,” as granted by the U.S. Patent and Trademark Office. The issued patent claims cover systems for determining the activation state of more than one protein in a cell, where the system can utilize any detector, including cytometers and mass spectrometers. The ‘527 patent extends through September 2023 and is exclusively licensed by Nodality from Stanford University.

“The ‘527 patent is another important protection for our multifaceted approach to improving drug development through diverse applications of our Single Cell Network Profiling platform,” said Laura Brege, CEO and President of Nodality, Inc. “Nodality has carefully constructed a patent estate consisting of more than 30 issued and allowed patents in the US and abroad, with over 260 issued claims, particularly in relation to the detection of activatable proteins that can be analyzed in healthy and diseased tissues, as well as in response to the application of new therapeutic modalities. We believe we have a commanding IP position in our space, which is an important aspect of the value proposition we offer to current and potential collaborators.” In addition to the issued and allowed patents, Nodality’s intellectual property estate also consists of more than 60 patent applications both in the US and ex-US.

About Single Cell Network Profiling

Contemporary pharmaceutical research and development remains challenged in producing drugs able to revolutionize the treatment of many of our most intractable diseases. Nodality's proprietary Single Cell Network Profiling (SCNP) offers solutions across broad therapeutic categories that demand higher levels of biological understanding to inform effective drug development decisions. Today, Nodality focuses its SCNP platform on immunology and oncology, including immuno-oncology.

Originally developed at Stanford University, SCNP is a multiparametric flow cytometry-based assay that provides unprecedented insights into diseases by characterizing cell signaling networks in millions of cells at the single cell level. SCNP measures functional protein pathway signaling networks within and between cells, identifying rare cell subsets, such as drug-resistant cells, revealing epigenetic changes in cells, and perceiving cell-cell interactions in complex disease states.

About Nodality

Nodality is advancing drug discovery, therapeutic development, and precision medicine by delivering critical and clinically actionable information to bridge gaps left by traditional R&D approaches. Nodality's proprietary functional biology platform, Single Cell Network Profiling (SCNP), unlocks highly complex intracellular mechanisms and cellular interactions in human diseases and has the power to shed light on some of the pharmaceutical industry's most challenging R&D problems. SCNP enables smarter spending decisions and is applicable across a very broad therapeutic landscape and throughout the full discovery and development process. Nodality has established multi-year strategic collaborations with UCB Pharma S.A. (Euronext Brussels: UCB), Pfizer (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ), utilizing its SCNP technology to assist the discovery and development of new therapeutic compounds.

For more information on Nodality, please visit www.nodalityinc.com.




Nodality, Inc.

Kathy LaPorte, 650-827-8022

Chief Business Officer

or

Burns McClellan

Media:

Justin Jackson, 212-213-0006, ext. 327

jjackson@burnsmc.com

Source: Nodality, Inc.


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Business Wire


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters